한글목차

세계의 신경 바이오마커 시장 규모는 2024년에 87억 달러에 달하며, 2030년까지 CAGR은 8.10%로 예측 기간 중 대폭적인 성장이 전망되고 있습니다.

신경 바이오마커 시장은 헬스케어 및 생명과학 산업에서 역동적이고 빠르게 발전하고 있는 분야입니다. 신경 바이오마커는 중추신경계와 말초신경계 모두에 영향을 미치는 신경질환의 진단, 모니터링 및 연구에 사용되는 필수적인 툴입니다. 이 시장은 현대 의학 및 연구에서 바이오마커의 중요한 역할을 강조하는 요인으로 인해 최근 수년간 크게 성장하고 있습니다. 이 분야는 신경질환의 유병률 증가, 바이오마커의 발견 및 검증의 발전, 고령화 인구 증가 등의 영향을 받아 앞으로도 계속 확대될 것으로 예상됩니다. 신경질환이 확산됨에 따라 조기에 정확한 진단 툴에 대한 수요가 급증하면서 시장 성장을 촉진하고 있습니다.

시장 성장 촉진요인

신경질환 유병률 증가

주요 시장이 해결해야 할 과제

신경질환의 복잡성

주요 시장 동향

맞춤형 의료의 부상

목차

제1장 개요

제2장 조사 방법

제3장 개요

제4장 고객의 소리

제5장 신경 바이오마커 시장 전망

• 시장 규모·예측
  • 금액별
• 시장 점유율·예측
  • 유형별(이미징, 프로테옴, 유전체학, 대사체학, 기타)
  • 용도별(다발성 경화증, 알츠하이머병, 자폐 스펙트럼 장애, 파킨슨병, 기타)
  • 최종사용자별(조사기관, 병원 및 병원 연구소, 독립 임상 진단 센터, 기타)
  • 지역별
  • 기업별(2024)
• 시장 맵

제6장 북미의 신경 바이오마커 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 북미 : 국가별 분석
  • 캐나다
  • 멕시코

제7장 유럽의 신경 바이오마커 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 유럽 : 국가별 분석
  • 영국
  • 이탈리아
  • 프랑스
  • 스페인

제8장 아시아태평양의 신경 바이오마커 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 아시아태평양 : 국가별 분석
  • 인도
  • 일본
  • 한국
  • 호주

제9장 남미의 신경 바이오마커 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 남미 : 국가별 분석
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 신경 바이오마커 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 중동 및 아프리카 : 국가별 분석
  • 사우디아라비아
  • 아랍에미리트

제11장 시장 역학

• 촉진요인
• 과제

제12장 시장 동향과 발전

• 최근 동향
• 제품 출시
• 합병과 인수

제13장 세계의 신경 바이오마커 시장 : SWOT 분석

제14장 경쟁 구도

• PERKINELMER INC.
• Abbott Laboratories Inc
• Thermo Fisher Scientific, Inc.
• Banyan Biomarkers, Inc.
• Bio-Rad Laboratories, Inc.
• F. HOFFMANN-LA ROCHE LTD.
• Merck & Co., Inc.
• DiaGenic ASA
• Johnson & Johnson Services, Inc.
• Myriad Genetics, Inc

제15장 전략적 제안

제16장 조사회사 소개·면책사항

영문목차

The Global Neurological Biomarkers Market was valued at USD 8.70 billion in 2024 and is projected to experience substantial growth during the forecast period, with a CAGR of 8.10% through 2030. This market represents a dynamic and rapidly advancing segment within the healthcare and life sciences industry. Neurological biomarkers are essential tools used for diagnosing, monitoring, and researching neurological disorders that affect both the central and peripheral nervous systems. The market has experienced significant growth in recent years, driven by factors that highlight the critical role of biomarkers in modern medicine and research. The sector is expected to continue its expansion, influenced by increasing prevalence of neurological disorders, advances in biomarker discovery and validation, and a growing aging population. As neurological conditions become more widespread, the demand for early, accurate diagnostic tools has surged, fueling market growth.

Key Market Drivers

Increasing Prevalence of Neurological Disorders

The growing incidence of neurological disorders globally plays a significant role in shaping the Neurological Biomarkers Market. As conditions such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, epilepsy, stroke, and traumatic brain injuries become more common, the need for advanced diagnostic tools, early detection methods, and precision treatment solutions has risen. Neurological biomarkers are critical in meeting these needs and driving market growth. These disorders are major contributors to disability and mortality worldwide, affecting over one in three individuals. In 2021, stroke was identified as the leading cause of health loss among the top neurological conditions. This rising disease burden has emphasized the need for early and accurate diagnostic solutions, thereby increasing the demand for neurological biomarkers.

The global aging population has resulted in an increase in neurodegenerative diseases, particularly Alzheimer's. The global dementia population is expected to nearly double every 20 years, reaching 78 million by 2030 and 139 million by 2050. A large proportion of this growth is expected in developing countries, where dementia prevalence is rapidly rising. Currently, 60% of dementia cases occur in low- and middle-income nations, with this figure projected to rise to 71% by 2050, underscoring the urgent need for expanded healthcare infrastructure, diagnostic capabilities, and intervention strategies in these regions. Biomarkers are increasingly incorporated into diagnostic protocols to detect Alzheimer's at early or pre-symptomatic stages.

In the United States, approximately one million individuals are diagnosed with Parkinson's disease (PD), and this number is expected to increase to 1.2 million by 2030. As the second most prevalent neurodegenerative disorder after Alzheimer's, Parkinson's presents a growing public health challenge, driving demand for advanced diagnostics, early detection, and innovative treatment solutions. Additionally, approximately one in four adults worldwide is at risk of experiencing a stroke, with over 12 million individuals expected to have their first stroke this year, leading to an anticipated 6.5 million fatalities. More than 100 million people globally are living with the long-term effects of stroke, highlighting the urgent need for improved prevention, early detection, and treatment options. Neurological biomarkers such as glial fibrillary acidic protein (GFAP) and S100B are widely used in stroke detection and brain injury assessment, further driving market growth. As more healthcare providers adopt biomarker-based diagnostic tests, the market continues to expand.

Key Market Challenges

Complexity of Neurological Disorders

A significant challenge in the development and adoption of neurological biomarkers is the complexity of neurological disorders. These conditions span a wide range of diseases, each with its unique characteristics and mechanisms. Disorders such as Alzheimer's, Parkinson's, and multiple sclerosis exhibit considerable heterogeneity among patients, making it difficult to identify universal biomarkers applicable to all cases. This complexity necessitates the discovery and validation of diverse biomarkers, a process that can be both time-consuming and resource-intensive. Furthermore, the concept of precision medicine, which tailors treatment to individual patients based on their unique biomarker profiles, complicates the development of standardized biomarkers. Customized biomarker panels may be required for each patient, increasing the need for personalized medicine approaches.

Key Market Trends

Rise of Personalized Medicine

A key trend in the Global Neurological Biomarkers Market is the shift toward personalized medicine, which involves tailoring medical treatments to individual patients based on their genetic, biomarker, and clinical profiles. This trend is fueled by advances in genomics and biomarker technologies, which allow for more precise disease predictions and treatment planning. The sequencing of the human genome, along with high-throughput genomics technologies, has enabled the identification of genetic variations associated with neurological disorders. These genetic biomarkers are used to assess disease risk and develop personalized treatment strategies. Additionally, biomarker panels that incorporate genetic, proteomic, and imaging data are being developed to provide more accurate diagnoses and differentiate between various subtypes of neurological disorders.

Personalized medicine enhances treatment effectiveness by selecting therapies that are most likely to work for individual patients, thereby minimizing the risk of adverse effects and optimizing therapeutic outcomes.

Key Market Players

• PerkinElmer Inc.
• Abbott Laboratories Inc.
• Thermo Fisher Scientific Inc.
• Banyan Biomarkers Inc.
• Bio-Rad Laboratories Inc.
• F. Hoffmann-La Roche Ltd.
• Merck & Co., Inc.
• DiaGenic ASA
• Johnson & Johnson Services Inc.
• Myriad Genetics Inc.

Report Scope

This report segments the Global Neurological Biomarkers Market into the following categories, in addition to detailing the industry trends:

Neurological Biomarkers Market, by Type:

• Imaging
• Proteomic
• Genomic
• Metabolomic
• Others

Neurological Biomarkers Market, by Application:

• Multiple Sclerosis
• Alzheimer's Disease
• Autism Spectrum Disorder
• Parkinson's Disease
• Others

Neurological Biomarkers Market, by End-User:

• Research Organizations
• Hospitals and Hospital Laboratories
• Independent Clinical Diagnostic Centers
• Others

Neurological Biomarkers Market, by Region:

• North America (United States, Canada, Mexico)
• Europe (France, United Kingdom, Italy, Germany, Spain)
• Asia-Pacific (China, India, Japan, Australia, South Korea)
• South America (Brazil, Argentina, Colombia)
• Middle East & Africa (South Africa, Saudi Arabia, UAE)

Competitive Landscape

The report includes detailed company profiles of the major players in the Global Neurological Biomarkers Market.

Available Customizations:

This report on the Global Neurological Biomarkers Market includes customized options to cater to a company's specific needs. The following customizations are available:

• Company Information: Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Neurological Biomarkers Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Imaging, Proteomic, Genomic, Metabolomic, Others)
  • 5.2.2. By Application (Multiple Sclerosis, Alzheimer's Disease, Autism Spectrum Disorder, Parkinson's Disease, Others)
  • 5.2.3. By End-User (Research Organizations, Hospital & Hospital Laboratories, Independent Clinical Diagnostic Centers, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Neurological Biomarkers Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Neurological Biomarkers Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Neurological Biomarkers Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Neurological Biomarkers Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe Neurological Biomarkers Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Neurological Biomarkers Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. United Kingdom Neurological Biomarkers Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. Italy Neurological Biomarkers Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. France Neurological Biomarkers Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Neurological Biomarkers Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia-Pacific Neurological Biomarkers Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Neurological Biomarkers Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. India Neurological Biomarkers Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Neurological Biomarkers Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Neurological Biomarkers Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Neurological Biomarkers Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. South America Neurological Biomarkers Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Neurological Biomarkers Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina Neurological Biomarkers Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia Neurological Biomarkers Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. Middle East and Africa Neurological Biomarkers Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Neurological Biomarkers Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia Neurological Biomarkers Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. UAE Neurological Biomarkers Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Neurological Biomarkers Market: SWOT Analysis

14. Competitive Landscape

• 14.1. PERKINELMER INC.
  • 14.1.1. Business Overview
  • 14.1.2. Product & Service Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Financials (If Listed)
  • 14.1.5. Key Personnel
  • 14.1.6. SWOT Analysis
• 14.2. Abbott Laboratories Inc
• 14.3. Thermo Fisher Scientific, Inc.
• 14.4. Banyan Biomarkers, Inc.
• 14.5. Bio-Rad Laboratories, Inc.
• 14.6. F. HOFFMANN-LA ROCHE LTD.
• 14.7. Merck & Co., Inc.
• 14.8. DiaGenic ASA
• 14.9. Johnson & Johnson Services, Inc.
• 14.10.Myriad Genetics, Inc

15. Strategic Recommendations

16. About Us & Disclaimer